Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Medical Devices

DexCom Inc. operates as a medical device company focused on the design and development of continuous glucose monitoring systems for people with diabetes. The Company has developed a small implantable device that continuously measures glucose levels in subcutaneous tissue just under the skin and a small external receiver to which the sensor transmits glucose levels at specified intervals.
Website: dexcom.com



Growth: Good revenue growth rate 13.1%, there is slowdown compared to average historical growth rates 17.3%. The revenue growth dynamics is moderately stable Site traffic for the last 3 months showed a change of +18.9%

Profitability: LTM EBITDA margin is positive, +22.6%. In the last quarter the company beat the estimated EPS, +13.3%. The company was ahead of estimated EPS in 60% of quarters (showing a gain of +$0.01 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 2.6% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 33.7% higher than minimum and 47.8% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 3.4x by EV / Sales multiple , the company can be 43.3% overvalued

Insiders: For the last 3 months insiders sold company shares on $0.2 mln (-0.001% of cap.)

Key Financials (Download financials)

Ticker: DXCM
Share price, USD:  (0.0%)73.34
year average price 74.27  


year start price 89.07 2025-02-14

max close price 90.75 2025-02-24

min close price 54.84 2025-11-10

current price 73.34 2026-02-13
Common stocks: 392 503 987

Dividend Yield:  0.0%
FCF Yield LTM: 2.6%
EV / LTM EBITDA: 26.7x
EV / EBITDA annualized: 20.0x
Last revenue growth (y/y):  +13.1%
Last growth of EBITDA (y/y):  +61.5%
Historical revenue growth:  +17.3%
Historical growth of EBITDA:  +36.1%
EV / Sales: 6.0x
Margin (EBITDA LTM / Revenue): 22.6%
Fundamental value created in LTM:
Market Cap ($m): 28 786
Net Debt ($m): -663
EV (Enterprise Value): 28 123
Price to Book: 10.6x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-02-05zacks.com

DXCM Upgrades Stelo With AI-Powered Smart Meal Logging Features

2026-01-28zacks.com

Here's Why DexCom (DXCM) is a Strong Momentum Stock

2026-01-21fool.com

1 Growth Stock Down 19% to Buy Right Now

2026-01-16zacks.com

DexCom Stock Declines Following Strong Preliminary Q4 Results

2026-01-15businesswire.com

Halper Sadeh LLC Encourages DexCom, Inc. Shareholders to Contact the Firm to Discuss Their Rights

2026-01-13youtube.com

Watch CNBC's exclusive interview with Dexcom CEO Jake Leach

2026-01-13seekingalpha.com

DexCom, Inc. (DXCM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2025-12-30zacks.com

3 Stocks Likely to Gain From Rising HSA Contribution & Medicare Premium

2025-12-26globenewswire.com

DXCM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that DexCom, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

2025-12-24zacks.com

Why DexCom (DXCM) is a Top Growth Stock for the Long-Term
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol DXCM DXCM DXCM DXCM DXCM DXCM DXCM DXCM DXCM DXCM DXCM DXCM DXCM DXCM
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-10-30 2025-07-30 2024-10-24 2024-07-25 2024-04-25 2023-10-26 2023-07-27 2023-04-27 2022-10-27
acceptedDate 2025-10-30 17:19:54 2025-07-30 17:19:57 2024-12-31 00:00:00 2024-10-24 17:13:02 2024-07-25 17:18:18 2024-04-25 17:17:02 2024-02-08 17:14:40 2023-10-26 17:14:39 2023-07-27 17:08:03 2023-04-27 17:10:57 2023-02-09 17:06:55 2022-10-27 17:11:18 2022-02-14 16:31:44 2021-02-11 17:18:05
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 1 209M 1 157M 4 033M 994M 1 004M 921M 3 622M 975M 871M 742M 2 910M 770M 2 449M 1 927M
costOfRevenue 478M 468M 1 595M 400M 378M 359M 1 333M 352M 325M 279M 1 027M 275M 768M 647M
grossProfit 731M 689M 2 438M 594M 627M 562M 2 289M 623M 546M 463M 1 883M 494M 1 681M 1 280M
grossProfitRatio 0.605 0.595 0.597 0.624 0.61 0.639 0.627 0.624 0.642
researchAndDevelopmentExpenses 158M 148M 552M 135M 136M 142M 506M 131M 119M 119M 484M 110M 604M 360M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 331M 328M 1 286M 306M 333M 319M 1 185M 285M 297M 295M 1 008M 235M 811M 621M
otherExpenses 0 0 0 0 -2M -300 000 0 34M 0 2M 0 2M 0 0
operatingExpenses 489M 476M 1 838M 442M 469M 461M 1 691M 418M 418M 415M 1 492M 347M 1 415M 981M
costAndExpenses 967M 945M 3 433M 842M 846M 820M 3 025M 770M 743M 694M 2 519M 622M 2 183M 1 627M
interestIncome 33M 28M 134M 32M 36M 36M 135M 42M 37M 22M 24M 3M 2M 16M
interestExpense 5M 5M 19M 5M 5M 5M 20M 5M 6M 5M 19M 5M 19M 85M
depreciationAndAmortization 64M 63M 218M 55M 52M 53M 186M 2M 2M 42M 156M 43M 102M 67M
ebitda 421M 309M 946M 237M 245M 190M 917M 207M 167M 111M 565M 190M 378M 377M
ebitdaratio 0.348 0.267 0.239 0.209 0.206 0.213 0.192 0.149 0.247
operatingIncome 243M 213M 600M 152M 158M 101M 598M 206M 128M 69M 391M 148M 266M 300M
operatingIncomeRatio 0.201 0.184 0.153 0.157 0.11 0.211 0.147 0.093 0.192
totalOtherIncomeExpensesNet 110M 29M 109M 25M 30M -300 000 113M 35M 31M -5M -400 000 -1M -9M -75M
incomeBeforeTax 352M 241M 709M 177M 188M 133M 710M 240M 159M 65M 391M 146M 257M 225M
incomeBeforeTaxRatio 0.291 0.208 0.178 0.187 0.144 0.247 0.183 0.087 0.19
incomeTaxExpense 69M 61M 133M 43M 44M -14M 169M 120M 43M 16M 50M 45M 40M -269M
netIncome 284M 180M 576M 135M 144M 146M 542M 121M 116M 49M 341M 101M 217M 494M
netIncomeRatio 0.235 0.155 0.135 0.143 0.159 0.124 0.133 0.066 0.131
eps 0.73 0.46 1.46 0.35 0.36 0.38 1.44 0.31 0.3 0.13 0.88 0.26 0.56 1.31
epsdiluted 0.7 0.45 0.34 0.35 0.36 0.29 0.28 0.12 0.24
weightedAverageShsOut 391M 392M 405M 394M 399M 390M 386M 387M 387M 387M 389M 390M 387M 378M
weightedAverageShsOutDil 407M 408M 413M 410M 417M 417M 426M 427M 432M 419M 428M 426M 429M 390M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2024-12-31 2024-02-08 2023-02-09 2022-02-14 2021-02-11
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 115M 115M 5M -17M -69M
ebit 728M 731M 409M 276M 310M
nonOperatingIncomeExcludingInterest -128M -133M -18M -10M -10M
netIncomeFromContinuingOperations 576M 542M 341M 217M 494M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions -12M -13M -11M -11M 0
bottomLineNetIncome 588M 554M 352M 228M 494M
epsDiluted 1.42 1.3 0.8 0.51 1.27

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol DXCM DXCM DXCM DXCM DXCM DXCM DXCM DXCM DXCM DXCM DXCM DXCM DXCM DXCM
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-10-30 2025-07-30 2024-10-24 2024-07-25 2024-04-25 2023-10-26 2023-07-27 2023-04-27 2022-10-27
acceptedDate 2025-10-30 17:19:54 2025-07-30 17:19:57 2024-12-31 00:00:00 2024-10-24 17:13:02 2024-07-25 17:18:18 2024-04-25 17:17:02 2024-02-08 17:14:40 2023-10-26 17:14:39 2023-07-27 17:08:03 2023-04-27 17:10:57 2023-02-09 17:06:55 2022-10-27 17:11:18 2022-02-14 16:31:44 2021-02-11 17:18:05
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 1 836M 1 159M 606M 621M 939M 851M 566M 644M 1 195M 623M 642M 698M 1 053M 818M
shortTermInvestments 1 486M 1 770M 1 973M 1 871M 2 182M 2 046M 2 158M 2 597M 2 441M 1 944M 1 814M 1 674M 1 679M 1 890M
cashAndShortTermInvestments 3 322M 2 929M 2 579M 2 492M 3 121M 2 897M 2 724M 3 240M 3 636M 2 567M 2 456M 2 372M 2 731M 2 708M
netReceivables 1 110M 1 377M 1 034M 1 034M 999M 985M 988M 786M 751M 653M 752M 597M 517M 429M
inventory 604M 571M 543M 586M 570M 589M 560M 499M 421M 366M 307M 311M 357M 235M
otherCurrentAssets 184M 153M 58M 151M 159M 40M 65M 174M 195M 43M 37M 119M 27M 0
totalCurrentAssets 5 220M 5 030M 4 301M 4 263M 4 848M 4 621M 4 426M 4 698M 5 003M 3 767M 3 669M 3 399M 3 684M 3 425M
propertyPlantEquipmentNet 1 525M 1 514M 1 403M 1 386M 1 254M 1 177M 1 185M 1 152M 1 154M 1 154M 1 136M 1 076M 890M 609M
goodwill 24M 24M 23M 24M 23M 23M 25M 25M 26M 26M 26M 25M 27M 19M
intangibleAssets 79M 87M 103M 106M 115M 123M 135M 145M 154M 164M 173M 24M 32M 21M
goodwillAndIntangibleAssets 103M 111M 126M 130M 138M 147M 160M 170M 180M 189M 199M 49M 58M 41M
longTermInvestments 0 116M 119M 46M 44M 40M 39M 39M 0 0 19M 0 0 0
taxAssets 376M 496M 481M 487M 476M 461M 419M 501M 417M 349M 341M 342M 291M 216M
otherNonCurrentAssets 277M 60M 54M 42M 39M 38M 37M 36M 67M 57M 28M 34M 11M 0
totalNonCurrentAssets 2 281M 2 297M 2 183M 2 091M 1 951M 1 862M 1 839M 1 898M 1 818M 1 749M 1 723M 1 501M 1 249M 866M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 7 500M 7 327M 6 485M 6 354M 6 799M 6 482M 6 265M 6 596M 6 821M 5 516M 5 392M 4 899M 4 933M 4 291M
accountPayables 1 932M 472M 345M 327M 307M 270M 276M 1 373M 1 157M 266M 238M 198M 189M 163M
shortTermDebt 1 231M 1 230M 1 204M 45M 43M 21M 0 145M 796M 795M 773M 21M 0 0
taxPayables 47M 47M 42M 44M 1 000 000 55M 50M 219M 60M 52M 45M 34M 41M 15M
deferredRevenue 3M 6M 8M 14M 15M 16M 18M 9M 9M 10M 10M 3M 2M 2M
otherCurrentLiabilities 123M 1 554M 56M 1 305M 1 356M 1 287M 46M 151M 109M 794M 48M 679M 48M 27M
totalCurrentLiabilities 3 336M 3 309M 2 932M 1 735M 1 722M 1 594M 1 556M 1 679M 2 070M 1 865M 1 839M 901M 721M 614M
longTermDebt 1 291M 1 350M 1 237M 2 569M 2 573M 2 569M 2 434M 2 516M 2 518M 1 347M 1 198M 2 111M 1 982M 1 667M
deferredRevenueNonCurrent 6M 6M 10M 5M 5M 7M 7M 21M 21M 21M 19M 24M 16M 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 44M 60M 0 5M 5M 5M 5M 5M 6M 0
otherNonCurrentLiabilities 141M 95M 80M 66M 65M 5M 60M 108M 107M 45M 45M 1 953M 11M 27M
totalNonCurrentLiabilities 1 438M 1 445M 1 450M 2 640M 2 643M 2 641M 2 640M 2 650M 2 651M 1 418M 1 421M 2 174M 2 170M 1 850M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 51M 134M 146M 152M 157M 154M 160M 104M 109M 171M 175M 163M 176M 172M
totalLiabilities 4 774M 4 754M 4 382M 4 375M 4 365M 4 235M 4 196M 4 328M 4 720M 3 283M 3 260M 3 075M 2 891M 2 464M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 400 000 400 000 400 000 400 000 400 000 400 000 400 000 400 000 400 000 400 000 400 000 400 000 400 000 100 000
retainedEarnings 2 167M 1 883M 1 598M 1 446M 1 311M 1 168M 1 021M 765M 644M 529M 480M 388M 139M -202M
accumulatedOtherComprehensiveIncomeLoss 82M 84M -8M 63M -38M -37M -17M -36M -29M -7M -12M -41M 500 000 3M
othertotalStockholdersEquity 478M 606M 469M 1 161M 1 116M 1 538M 1 485M 1 711M 1 477M
totalStockholdersEquity 2 726M 2 573M 2 103M 1 979M 2 434M 2 247M 2 069M 2 268M 2 100M 2 233M 2 132M 1 825M 2 042M 1 827M
totalEquity 2 726M 2 573M 2 103M 1 979M 2 434M 2 247M 2 069M 2 268M 2 100M 2 233M 2 132M 1 825M 2 042M 1 827M
totalLiabilitiesAndStockholdersEquity 7 500M 7 327M 6 354M 6 799M 6 482M 6 596M 6 821M 5 516M 4 899M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 7 500M 7 327M 6 485M 6 354M 6 799M 6 482M 6 265M 6 596M 6 821M 5 516M 5 392M 4 899M 4 933M 4 291M
totalInvestments 1 486M 1 886M 2 093M 1 917M 2 225M 2 046M 2 196M 2 597M 2 441M 1 944M 1 833M 1 674M 1 679M 1 890M
totalDebt 2 521M 2 579M 2 587M 2 591M 2 594M 2 590M 2 594M 2 661M 3 313M 2 143M 2 145M 2 132M 2 158M 1 840M
netDebt 685M 1 420M 1 981M 1 970M 1 655M 1 739M 2 028M 2 017M 2 118M 1 520M 1 503M 1 434M 1 105M 1 022M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2024-12-31 2024-02-08 2023-02-09 2022-02-14 2021-02-11
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 1 006M 974M 713M 514M 429M
otherReceivables 28M 14M 39M 2M 0
prepaids 88M 90M 117M 52M 54M
totalPayables 388M 327M 283M 230M 179M
otherPayables 42M 50M 45M 41M 15M
accruedExpenses 1 253M 1 144M 706M 420M 390M
capitalLeaseObligationsCurrent 23M 21M 21M 21M 17M
capitalLeaseObligationsNonCurrent 124M 139M 154M 156M 156M
treasuryStock -1 581M -2 451M -595M -206M -100M
additionalPaidInCapital 2 094M 3 515M 2 258M 2 109M 2 125M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol DXCM DXCM DXCM DXCM DXCM DXCM DXCM DXCM DXCM DXCM DXCM DXCM DXCM DXCM
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-10-30 2025-07-30 2024-10-24 2024-07-25 2024-04-25 2023-10-26 2023-07-27 2023-04-27 2022-10-27
acceptedDate 2025-10-30 17:19:54 2025-07-30 17:19:57 2024-12-31 00:00:00 2024-10-24 17:13:02 2024-07-25 17:18:18 2024-04-25 17:17:02 2024-02-08 17:14:40 2023-10-26 17:14:39 2023-07-27 17:08:03 2023-04-27 17:10:57 2023-02-09 17:06:55 2022-10-27 17:11:18 2022-02-14 16:31:44 2021-02-11 17:18:05
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome 284M 180M 576M 135M 144M 146M 542M 121M 116M 49M 341M 101M 155M 494M
depreciationAndAmortization 64M 63M 218M 55M 52M 53M 186M 48M 44M 42M 156M 39M 102M 67M
deferredIncomeTax 118M -9M -44M -12M -15M -42M -55M -85M -42M -9M -22M -34M -5M -277M
stockBasedCompensation 45M 45M 170M 43M 45M 39M 151M 39M 40M 35M 127M 31M 113M 119M
changeInWorkingCapital -23M 22M 109M 16M 68M 19M 3M 163M 47M 52M 28M 138M -132M -21M
accountsReceivables 238M -185M -35M -56M 34M -6M -260M -36M -114M 77M -200M -5M -76M -142M
inventory -34M -19M 12M -2M 18M -37M -253M -79M -55M -60M 49M 27M -112M -115M
accountsPayables -2M 234M 212M 50M 72M 110M 467M 220M 190M 87M 295M 75M 58M 195M
otherWorkingCapital -225M -9M -80M 24M -57M 1M 49M 58M 26M -52M -117M 41M -2M 42M
otherNonCashItems 172M 1M -40M -38M 11M -6M -78M -17M -14M -12M 40M 17M 209M 94M
netCashProvidedByOperatingActivities 660M 303M 990M 200M 279M 209M 749M 269M 190M 155M 670M 293M 443M 476M
investmentsInPropertyPlantAndEquipment -81M -94M -359M -111M -66M -57M -237M -50M -59M -75M -365M -108M -389M -199M
acquisitionsNet 0 0 0 0 0 0 0 0 0 0 -4M -700 000 -30M 0
purchasesOfInvestments -194M -608M -2 658M -307M -784M -992M -3 200M -798M -1 340M -810M -2 266M -254M -2 473M -3 058M
salesMaturitiesOfInvestments 466M 639M 2 824M 631M 667M 1 122M 2 947M 671M 859M 698M 2 128M 602M 2 666M 2 251M
otherInvestingActivites 1 000 000 0 -2M -5M 2M -3M -16M 0 -10M
netCashUsedForInvestingActivites 193M -64M 210M -189M 75M -180M -556M -187M 229M
debtRepayment 0 0 0 0 0 -651M 0 0 0
commonStockIssued 14M 0 15M 0 13M 14M 0 12M 12M
commonStockRepurchased -187M 0 -750M -750M 0 0 -689M 0 0 0 -558M 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites -2M -2M -1M -1M -9M -1M 940M -1M -565M
netCashUsedProvidedByFinancingActivities -175M -2M -737M -1M 5M -637M 940M 11M -553M
effectOfForexChangesOnCash -1M 17M -7M 9M -1 000 000 -4M 2M -4M -2M 1M -6M -7M -1M 2M
netChangeInCash 677M 254M 40M -317M 88M 285M -76M -551M 572M -19M -410M -37M 235M 372M
cashAtEndOfPeriod 1 837M 1 160M 607M 622M 939M 852M 568M 645M 1 196M 624M 643M 699M 1 054M 818M
cashAtBeginningOfPeriod 1 160M 906M 568M 939M 851M 568M 643M 1 196M 624M 643M 1 054M 736M 818M 446M
operatingCashFlow 660M 303M 990M 200M 279M 209M 749M 269M 190M 155M 670M 293M 443M 476M
capitalExpenditure -81M -94M -359M -111M -66M -57M -237M -50M -59M -75M -365M -108M -389M -199M
freeCashFlow 579M 209M 631M 88M 213M 152M 512M 219M 131M 81M 305M 185M 53M 277M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2024-12-31 2024-02-08 2023-02-09 2022-02-14 2021-02-11
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities -16M -18M -14M 10M -11M
netCashProvidedByInvestingActivities -208M -507M -522M -216M -1 018M
netDebtIssuance 0 443M 0 0 906M
longTermNetDebtIssuance 0 443M 0 0 906M
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance -722M -662M -535M 20M 15M
netCommonStockIssuance -722M -662M -535M 20M 15M
commonStockIssuance 28M 27M 23M 20M 15M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities -13M -100M -17M -10M -9M
netCashProvidedByFinancingActivities -735M -319M -553M 10M 912M
incomeTaxesPaid 198M 212M 114M 17M 4M
interestPaid 11M 12M 12M 12M 11M

Earning call transcript

2025 q3
2025-10-30 ET (fiscal 2025 q3)
2025 q2
2025-07-30 ET (fiscal 2025 q2)
2025 q1
2025-05-01 ET (fiscal 2025 q1)
2024 q4
2025-02-13 ET (fiscal 2024 q4)
2024 q3
2024-10-24 ET (fiscal 2024 q3)
2024 q2
2024-07-25 ET (fiscal 2024 q2)
2024 q1
2024-04-25 ET (fiscal 2024 q1)
2023 q4
2024-02-08 ET (fiscal 2023 q4)
2023 q3
2023-10-26 ET (fiscal 2023 q3)
2023 q2
2023-07-27 ET (fiscal 2023 q2)
2023 q1
2023-04-27 ET (fiscal 2023 q1)
2022 q4
2023-02-09 ET (fiscal 2022 q4)
2022 q3
2022-10-27 ET (fiscal 2022 q3)
2022 q2
2022-07-28 ET (fiscal 2022 q2)
2022 q1
2022-04-28 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 10
2026-02-12 17:20 ET
DexCom reported for 2025 q4
SEC form 8
2026-02-12 16:03 ET
DexCom published news for 2025 q4
SEC form 8
2026-02-12 16:03 ET
DexCom reported for 2025 q4
SEC form 10
2025-10-30 21:19 ET
DexCom reported for 2025 q3
SEC form 8
2025-10-30 20:02 ET
DexCom published news for 2025 q3
SEC form 8
2025-10-30 20:02 ET
DexCom reported for 2025 q3
SEC form 10
2025-07-30 21:19 ET
DexCom reported for 2025 q2
SEC form 8
2025-07-30 20:02 ET
DexCom published news for 2025 q2
SEC form 8
2025-07-30 20:02 ET
DexCom reported for 2025 q2
SEC form 10
2025-05-01 21:15 ET
DexCom reported for 2025 q1
SEC form 8
2025-05-01 20:03 ET
DexCom published news for 2025 q1
SEC form 8
2025-05-01 20:03 ET
DexCom reported for 2025 q1
SEC form 10
2025-05-01 00:00 ET
DexCom reported for 2025 q1
SEC form 10
2025-02-18 00:00 ET
DexCom published news for 2024 q4
SEC form 8
2025-02-13 00:00 ET
DexCom published news for 2024 q4
SEC form 8
2025-02-13 00:00 ET
DexCom reported for 2024 q4
SEC form 8
2025-01-13 00:00 ET
DexCom published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
DexCom published news for 2024 q4
SEC form 10
2024-10-24 17:13 ET
DexCom reported for 2024 q3
SEC form 8
2024-10-24 16:04 ET
DexCom published news for 2024 q3
SEC form 8
2024-10-24 16:04 ET
DexCom reported for 2024 q3
SEC form 10
2024-10-24 00:00 ET
DexCom reported for 2024 q3
SEC form 10
2024-07-25 17:18 ET
DexCom published news for 2024 q2
SEC form 8
2024-07-25 16:05 ET
DexCom published news for 2024 q2
SEC form 8
2024-07-25 16:05 ET
DexCom reported for 2024 q2
SEC form 10
2024-07-25 00:00 ET
DexCom published news for 2024 q2
SEC form 10
2024-04-25 17:17 ET
DexCom published news for 2024 q1
SEC form 8
2024-04-25 16:05 ET
DexCom published news for 2024 q1
SEC form 8
2024-04-25 16:05 ET
DexCom reported for 2024 q1
SEC form 10
2024-04-25 00:00 ET
DexCom published news for 2024 q1
SEC form 10
2024-02-08 00:00 ET
DexCom reported for 2023 q4
SEC form 8
2024-02-08 00:00 ET
DexCom published news for 2023 q4
SEC form 8
2024-02-08 00:00 ET
DexCom reported for 2023 q4
SEC form 8
2024-01-08 00:00 ET
DexCom published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
DexCom published news for 2023 q4
SEC form 10
2023-10-26 17:14 ET
DexCom published news for 2023 q3
SEC form 8
2023-10-26 16:04 ET
DexCom reported for 2023 q3
SEC form 10
2023-10-26 00:00 ET
DexCom published news for 2023 q3
SEC form 10
2023-07-27 17:08 ET
DexCom reported for 2023 q2
SEC form 6
2023-07-27 16:05 ET
DexCom published news for 2023 q2
SEC form 10
2023-07-27 00:00 ET
DexCom published news for 2023 q2
SEC form 8
2023-07-27 00:00 ET
DexCom published news for 2023 q2
SEC form 6
2023-06-23 18:04 ET
DexCom published news for 2023 q1
SEC form 10
2023-04-27 00:00 ET
DexCom published news for 2023 q1
SEC form 8
2023-04-27 00:00 ET
DexCom published news for 2023 q1
SEC form 10
2023-02-09 17:06 ET
DexCom published news for 2022 q4
SEC form 6
2023-02-09 16:05 ET
DexCom published news for 2022 q4
SEC form 10
2023-02-09 00:00 ET
DexCom published news for
SEC form 8
2023-02-09 00:00 ET
DexCom reported for 2022 q4
SEC form 6
2023-01-09 08:03 ET
DexCom published news for 2022 q4
SEC form 8
2023-01-09 00:00 ET
DexCom published news for 2022 q4
SEC form 10
2022-10-27 17:11 ET
DexCom published news for 2022 q3
SEC form 6
2022-10-27 16:05 ET
DexCom published news for 2022 q3
SEC form 10
2022-10-27 00:00 ET
DexCom reported for 2022 q3
SEC form 8
2022-10-27 00:00 ET
DexCom reported for 2022 q3
SEC form 6
2022-08-31 17:01 ET
DexCom published news for 2022 q2
SEC form 6
2022-08-05 16:52 ET
DexCom published news for 2022 q2
SEC form 10
2022-07-28 17:14 ET
DexCom published news for 2022 q2
SEC form 6
2022-07-28 16:23 ET
DexCom published news for 2022 q2
SEC form 6
2022-07-28 16:07 ET
DexCom published news for 2022 q2
SEC form 10
2022-07-28 00:00 ET
DexCom reported for 2022 q2
SEC form 8
2022-07-28 00:00 ET
DexCom reported for 2022 q2
SEC form 6
2022-07-08 16:30 ET
DexCom published news for 2022 q2
SEC form 6
2022-06-10 16:01 ET
DexCom published news for 2022 q1
SEC form 6
2022-05-20 09:01 ET
DexCom published news for 2022 q1
SEC form 10
2022-04-28 17:28 ET
DexCom published news for 2022 q1
SEC form 6
2022-04-28 16:08 ET
DexCom published news for 2022 q1
SEC form 10
2022-04-28 00:00 ET
DexCom reported for 2022 q1
SEC form 8
2022-04-28 00:00 ET
DexCom reported for 2022 q1
SEC form 6
2022-04-08 16:16 ET
DexCom published news for 2022 q1
SEC form 6
2022-03-25 16:25 ET
DexCom published news for 2021 q4
SEC form 6
2022-03-10 17:39 ET
DexCom published news for 2021 q4
SEC form 10
2022-02-14 16:31 ET
DexCom published news for 2021 q4
SEC form 10
2022-02-14 00:00 ET
DexCom published news for 2021 q4
SEC form 6
2022-02-10 16:08 ET
DexCom published news for 2021 q4
SEC form 8
2022-02-10 00:00 ET
DexCom published news for 2021 q4
SEC form 6
2022-01-26 17:42 ET
DexCom published news for 2021 q4
SEC form 6
2022-01-10 08:00 ET
DexCom published news for 2021 q4
SEC form 8
2022-01-10 00:00 ET
DexCom published news for 2021 q4
SEC form 6
2021-12-17 16:41 ET
DexCom published news for 2021 q3
SEC form 6
2021-11-22 17:03 ET
DexCom published news for 2021 q3
SEC form 10
2021-10-28 17:14 ET
DexCom published news for 2021 q3
SEC form 6
2021-10-28 16:06 ET
DexCom published news for 2021 q3
SEC form 10
2021-10-28 00:00 ET
DexCom published news for 2021 q3
SEC form 8
2021-10-28 00:00 ET
DexCom published news for 2021 q3
SEC form 6
2021-10-14 16:01 ET
DexCom published news for 2021 q3
SEC form 6
2021-09-14 16:29 ET
DexCom published news for 2021 q2
SEC form 6
2021-09-13 08:00 ET
DexCom published news for 2021 q2
SEC form 10
2021-07-29 17:19 ET
DexCom published news for 2021 q2
SEC form 6
2021-07-29 16:05 ET
DexCom published news for 2021 q2
SEC form 10
2021-07-29 00:00 ET
DexCom published news for 2021 q2
SEC form 8
2021-07-29 00:00 ET
DexCom published news for 2021 q2
SEC form 6
2021-06-30 18:58 ET
DexCom published news for 2021 q1
SEC form 6
2021-05-21 17:17 ET
DexCom published news for 2021 q1
SEC form 10
2021-04-29 17:17 ET
DexCom published news for 2021 q1
SEC form 6
2021-04-29 16:03 ET
DexCom published news for 2021 q1
SEC form 10
2021-04-29 00:00 ET
DexCom published news for 2021 q1
SEC form 8
2021-04-29 00:00 ET
DexCom published news for 2021 q1
SEC form 6
2021-04-09 16:32 ET
DexCom published news for 2021 q1
SEC form 6
2021-04-01 19:02 ET
DexCom published news for 2021 q1
SEC form 6
2021-04-01 18:56 ET
DexCom published news for 2021 q1
SEC form 6
2021-04-01 18:53 ET
DexCom published news for 2021 q1
SEC form 6
2021-03-26 16:08 ET
DexCom published news for 2020 q4
SEC form 6
2021-03-23 08:31 ET
DexCom published news for 2020 q4
SEC form 6
2021-03-17 14:22 ET
DexCom published news for 2020 q4
SEC form 10
2021-02-11 17:18 ET
DexCom published news for 2020 q4
SEC form 6
2021-02-11 16:04 ET
DexCom published news for 2020 q4
SEC form 6
2021-01-11 07:39 ET
DexCom published news for 2020 q4
SEC form 6
2020-12-10 16:15 ET
DexCom published news for 2020 q3
SEC form 6
2020-11-20 16:47 ET
DexCom published news for 2020 q3
SEC form 10
2020-10-27 17:11 ET
DexCom published news for 2020 q3
SEC form 6
2020-10-27 16:08 ET
DexCom published news for 2020 q3
SEC form 6
2020-10-26 17:24 ET
DexCom published news for 2020 q3
SEC form 6
2020-10-13 16:37 ET
DexCom published news for 2020 q3
SEC form 6
2020-10-13 10:50 ET
DexCom published news for 2020 q3
SEC form 6
2020-10-05 18:12 ET
DexCom published news for 2020 q3